(172 days)
Incstar HSV I/II IgG "fast" ELISA Kit
Not Found
No
The summary describes a standard ELISA assay for detecting antibodies and mentions an automated processor, but there is no indication of AI or ML being used for analysis or interpretation.
No
This device is an immunoassay for detecting antibodies to HSV, which aids in diagnosis. It does not provide any treatment or therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device is for "qualitative and semi-quantitative determination of IgG antibodies to herpes simplex virus (HSV) type 1 and/ or type 2 in human serum" and that it "can aid in the diagnosis of primary infection with HSV." This directly indicates a diagnostic purpose.
No
The device is an Enzyme Immunoassay (EIA) test system, which involves physical reagents and laboratory procedures, not solely software. While it can be used with an automated processor (which likely includes software), the core device itself is a biological assay kit.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the device is for the "qualitative and semi-quantitative determination of IgG antibodies to herpes simplex virus (HSV) type 1 and/ or type 2 in human serum." This indicates that the device is used to test a sample taken from the human body (serum) in vitro (outside the body) to provide information about a medical condition (presence of HSV antibodies).
- Device Description: The "Device Description" further clarifies that it is an "enzyme-linked immunosorbent assay (ELISA) for the detection and semi-quantitation of IgG to HSV 1 and/or HSV 2 antigens in human serum." ELISA is a common type of in vitro diagnostic test.
- Performance Studies: The document details performance studies conducted on human serum samples, including sensitivity, specificity, and agreement with other devices. This is typical for the evaluation of IVD devices.
- Predicate Device: The mention of a "Predicate Device" (Incstar HSV I/II IgG "fast" ELISA Kit) is also a strong indicator that this device is being compared to another legally marketed IVD.
All these points align with the definition and characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Diamedix Is-HSV 1 & 2 IgG is an indirect Enzyme Immunoassay (EIA) for the qualitative and semi-quantitative determination of IgG antibodies to herpes simplex virus (HSV) type 1 and/ or type 2 in human serum. This test is useful for indicating a past infection with HSV in a single specimen, including females of child-bearing age. The evaluation of acute and convalescent specimens, by demonstrating seroconversion or a significant increase in antibody level, can aid in the diagnosis of primary infection with HSV. These reagents can be used either manually or in conjunction with the MAGO® Plus Automated EIA Processor.
Product codes (comma separated list FDA assigned to the subject device)
LGC
Device Description
The Is-HSV 1 & 2 IgG Test System is an enzyme-linked immunosorbent assay (ELISA) for the detection and semi-quantitation of IgG to HSV 1 and/or HSV 2 antigens in human serum. Purified HSV 1 and 2 antigens are attached to a solid phase microtiter well. Diluted test sera are added to each well. If antibodies which recognize the HSV antigens are present in the patient sample they will bind to the antigens on the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human immunoglobulin (conjugate) is added to each test well. If antibody is present the enzyme-linked antibody will bind to it. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is then added to each well. If enzyme is present from the prior step, the reaction is stopped and the color intensity is measured photometrically producing an indirect measure of the specific antibody present in the patient sample.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A total of 645 different patient sera were evaluated. The CDC serum panel for HSV serology assays was also tested.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance Data : The Is-HSV 1 & 2 IgG Test System was evaluated relative to the predicate device and to other legally marketed devices at 3 different test sites. In addition, the CDC serum panel for HSV serology assays was tested with this device.
A total of 645 different patient sera were evaluated.
Results:
Site 1 (n=200): Relative Sensitivity (%) 100.0 (97.7-100.0), Relative Specificity (%) 92.7 (80.1-98.5), Overall Agreement* (%) 98.5 (95.6-99.7)
Site 2 (n=178): Relative Sensitivity (%) 99.2 (95.4-100.0), Relative Specificity (%) 94.7 (85.4-98.9), Overall Agreement* (%) 97.7 (94.3-99.4)
Site 3 (manual) (n=267): Relative Sensitivity (%) 100.0 (98.3-100.0), Relative Specificity (%) 100.0 (93.4-100.0), Overall Agreement* (%) 100.0 (98.6-100.0)
Site 3 (automated) (n=259): Relative Sensitivity (%) 99.5 (97.4-100.0), Relative Specificity (%) 97.8 (88.5-99.9), Overall Agreement* (%) 99.2 (97.2-99.9)
- equivocal samples were not included in calculations ) 95% confidence interval (
The precision of the Is-HSV1 & 2 IgG Test Sytem was determined at 3 testing sites by testing several sera in two different runs per day for three days. Intra-assay CVs for positive samples ranged from 1.4 to 18.7%. Interassay CVs for positive samples ranged from 3.5 to 15.5%.
Studies were also conducted to show the correlation between manual and automated methods for samples within the assay's critical range (20-100 EU/ml).
The titration of strongly positive samples demonstrate a linear relationship between the Is-HSV 1 & 2 IgG EU/ml values and the log of the serum dilution.
Studies undertaken to determine cross-reactivity of the Is-HSV 1 & 2 IgG Test System demonstrated no detectable cross-reactivity to varicella zoster virus, cytomegalovinus, Epstein Barr virus, measles virus, rubella virus or Toxoplasma.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Relative Sensitivity, Relative Specificity, Overall Agreement, Intra-assay CVs, Interassay CVs, Correlation, Linearity, Cross-reactivity.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Incstar HSV I/II IgG "fast" ELISA Kit
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.3305 Herpes simplex virus serological assays.
(a)
Identification. Herpes simplex virus serological assays are devices that consist of antigens and antisera used in various serological tests to identify antibodies to herpes simplex virus in serum. Additionally, some of the assays consist of herpes simplex virus antisera conjugated with a fluorescent dye (immunofluorescent assays) used to identify herpes simplex virus directly from clinical specimens or tissue culture isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by herpes simplex viruses and provides epidemiological information on these diseases. Herpes simplex viral infections range from common and mild lesions of the skin and mucous membranes to a severe form of encephalitis (inflammation of the brain). Neonatal herpes virus infections range from a mild infection to a severe generalized disease with a fatal outcome.(b)
Classification. Class II (special controls). The device is classified as class II (special controls). The special control for the device is FDA's revised guidance document entitled “Class II Special Controls Guidance Document: Herpes Simplex Virus Types 1 and 2 Serological Assays.” For availability of the guidance revised document, see § 866.1(e).
0
SEP 2 9 1998
510(k) Summary
This 510(k) summary is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
K981306 The assigned 510(k) number is:
Applicant Information:
| Date Prepared: | September 28, 1998 |
|---|---|
| Submitter's Name: | Diamedix Corporation |
| Address: | 2140 N. Miami Avenue |
| Miami, FL 33127 |
| Contact Person: | Dr. Lynne Stirling |
|---|---|
| Phone Number: | 305-324-2354 |
| Fax Number: | 305-324-2585 |
Device Information:
| Trade Name: | Is-HSV 1 & 2 IgG Test System |
|---|---|
| Common Name: | HSV EIA Test |
| Classification Name: | Enzyme linked immunosorbent assay, herpes simplex virus |
Equivalent Device Description:
Incstar HSV I/II IgG "fast" ELISA Kit
The Incstar Herpes Simplex Virus VII IgG "fast" ELISA kit contains instructions and materials for the qualitiative and semi-quantitative detection of IgG antibodies to herpes simplex virus type 1 and/or type 2 in human serum by indirect ELISA.
Device Description: The Is-HSV 1 & 2 IgG Test System is an enzyme-linked immunosorbent assay (ELISA) for the detection and semi-quantitation of IgG to HSV 1 and/or HSV 2 antigens in human serum
Device Intended Use: This device is intended for the qualitative and semi-quantitative detection of IgG antibodies to herves simplex virus (HSV) type 1 and/or type 2 in human serum. This test is useful for indicating a past infection with HSV in a single specimen, including females of child-bearing age. The evaluation of acute and convalescent specimens, by demonstrating seroconversion or a significant increase in antibody level, can aid in the diagnosis of primary infection with HSV. These reagents can be used either manually or in conjunction with the MAGO Plus Automated Processor.
Principle of the Procedure:
The Is-HSV 1 & 2 IgG Test System is an enzyme-linked immunosorbent assay to detect IgG to HSV1 and/or HSV 2 in human serum. Purified HSV 1 and 2 antigens are attached to a solid phase microtiter well. Diluted test sera are added to each well. If antibodies which recognize the HSV antigens are present in the patient sample they will bind to the antigens on the well. After incubation, the wells are washed to remove unbound antibody. An enzyme
1
labeled anti-human immunoglobulin (conjugate) is added to each test well. If antibody is present the enzyme-linked antibody will bind to it. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is then added to each well. If enzyme is present from the prior step, the reaction is stopped and the color intensity is measured photometrically producing an indirect measure of the specific antibody present in the patient sample.
The Is-HSV 1 & 2 IgG Test System and the Incstar HSV I/II IgG "fast" ELISA are substantially equivalent in that :
-
- Both are in vitro immunologic methods
-
- Both are intended for use in the detection of IgG antibody to herpes simplex virus type 1 and/or type 2 in human serum.
-
- Both are based on the formation of a complex between HSV antigens and antibody
-
- Both use antigen coated microtiter plates
-
- Both are qualitative/semi-quantitative assays
-
- Both use goat anti-human IgG conjugated to horseradish peroxidase
-
- Both use TMB as the enzyme substrate.
A detailed comparison between the proposed device and the predicate device is shown in Table 1.
Performance Data : The Is-HSV 1 & 2 IgG Test System was evaluated relative to the predicate device and to other legally maketed devices at 3 different test sites. In addition, the CDC serum panel for HSV serology assays was tested with this device.
A total of 645 different patient sera were evaluated. Thes results of these comparisons are shown below :
| | # of Sera | Relative
Sensitivity (%) | Relative
Specificity (%) | Overall
Agreement* (%) |
|--------------------|-----------|-----------------------------|-----------------------------|---------------------------|
| Site 1 | 200 | 100.0
(97.7-100.0) | 92.7
(80.1-98.5) | 98.5
(95.6-99.7) |
| Site 2 | 178 | 99.2
(95.4-100.0) | 94.7
(85.4-98.9) | 97.7
(94.3-99.4) |
| Site 3 (manual) | 267 | 100.0
(98.3-100.0) | 100.0
(93.4-100.0) | 100.0
(98.6-100.0) |
| Site 3 (automated) | 259 | 99.5
(97.4-100.0) | 97.8
(88.5-99.9) | 99.2
(97.2-99.9) |
- equivocal samples were not included in calculations
) 95% confidence interval (
2
The precision of the Is-HSV1 & 2 IgG Test Sytem was determined at 3 testing sites by testing several sera in two different runs per day for threee days. Intra-assay CVs for positive samples ranged from 1.4 to 18.7%. Interassay CVs for positive samples ranged from 3.5 to 15.5%.
Studies were also conducted to show the correlation between manual and autmated methods for samples within the assay's critical range (20-100 EU/ml).
The titration of strongly positive sampes demonstrate a linear relationship between the Is-HSV 1 & 2 IgG EU/ml values and the log of the serum dilution.
Studies undertaken to determine cross-reactivity of the Is-HSV 1 & 2 IgG Test System demonstrated no detectable cross-reactivity to varicella zoster virus, cytomegalovinus, Epstein Barr virus, measles virus, rubella virus or Toxoplasma.
Conclusions : The Diamedix Is-HSV 1 & 2 IgG is substantially equivalent to the Incstar HSV VII "fast" ELISA for the detection of IgG antibodies to herpes simplex virus in human serum to aid in the indication of a past infection or, in the case of paired samples, as an aid in the diagnosis of a primary infection. The device is as safe, as effective and performs as well as the legally marketed device described.
3
Public Health Service
Image /page/3/Picture/2 description: The image shows the logo for the Department of Health & Human Services USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle or bird-like figure, with three curved lines forming the body and wings.
SEP 2 9 1998
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Lynne Stirling, Ph.D. Vice President, Regulatory Affairs Diamedix Corporation 2140 N. Miami Ave. Miami, FL 33127
Re: K981306 Trade Name: Is-HSV 1 & 2 IgG Test System Regulatory Class: III Product Code: LGC Dated: July 14, 1998 Received: July 17, 1998
Dear Dr. Stirling:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
4
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours.
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Appendix G Rev. Indications for Use Statement
INDICATIONS FOR USE STATEMENT
510(K) Number : _ K 981366
DEVICE NAME : Is-HSV 1 & 2 IgG Test System
Indications for Use : The Diamedix Is-HSV 1 & 2 IgG is an indirect Enzyme Immunoassay (EIA) for the qualitative and semi-quantitative determination of IgG antibodies to herpes simplex virus (HSV) type 1 and/ or type 2 in human serum. This test is useful for indicating a past infection with HSV in a single specimen, including females of child-bearing age. The evaluation of acute and convalescent specimens, by demonstrating seroconversion or a significant increase in antibody level, can aid in the diagnosis of primary infection with HSV. These reagents can be used either manually or in conjunction with the MAGO® Plus Automated EIA Processor.
Woody Dubois
ion of Clinical Laboratory Devices 510(k) Number